Group 2

ADAMA Set to Bring Innovation to the European Cereal Herbicide Segment with the Introduction of EDAPTIS®

Retrieved on: 
Montag, Mai 6, 2024
TEL, Rapeseed oil, Thought, Research, Group 1, Farmer, Group 2, Weed control, Agriculture

EDAPTIS® is a ready-to-use solution that provides broad-spectrum control of grassy weeds and improved efficacy in combating resistant populations.

Key Points: 
  • EDAPTIS® is a ready-to-use solution that provides broad-spectrum control of grassy weeds and improved efficacy in combating resistant populations.
  • Leading research in herbicide resistance suggests that stacking modes of action are more effective in mitigating herbicide resistance compared to the conventional practice of rotating herbicide groups.
  • This urgency is compounded by the removal of numerous herbicides, especially in the pre-emergent segment, due to heightened regulatory restrictions," said Darren Palendat, Global Herbicide Product Strategy for ADAMA.
  • EDAPTIS® received registration in Poland and is expected to be registered in multiple European countries including France, Germany, UK, Italy, Spain and others.

Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections

Retrieved on: 
Donnerstag, April 18, 2024
Șaeș, Cancer, Safety, Woman, Month, Group 2, HPV, Aes, APOLLO, Immune system, Autoimmunity, Ageing, Birth control

Pooled data from the five different active dose groups demonstrated no statistically significant improvement in either hrHPV or cervical lesion clearance in comparison to the placebo group.

Key Points: 
  • Pooled data from the five different active dose groups demonstrated no statistically significant improvement in either hrHPV or cervical lesion clearance in comparison to the placebo group.
  • “This was our first in-human, dose-ranging trial of VTP-200 in women with hrHPV-associated low-grade cervical lesions, who currently don’t have any treatment option until progression to high-grade lesions,” said Bill Enright, Chief Executive Officer of Barinthus Bio.
  • “However, these differences compared to placebo were not statistically significant given that the trial was not powered for individual dose group comparisons.
  • Further analyses are ongoing, mostly focusing on immunological responses and we plan to share the detailed results in due course.”

RapidFlight Delivers UAS Innovation, Meeting Replicator Initiative Requirements

Retrieved on: 
Donnerstag, April 18, 2024
Group 3, Gasoline, Technology readiness, Unmanned aerial vehicle, DOD, San Diego Convention Center, EW, UAS, Group 2, Replicator, ISR, 3D printing

MANASSAS, Va., April 18, 2024 /PRNewswire/ -- RapidFlight, a pioneering integrated designer and mass manufacturer of unmanned aircraft systems (UAS), is working with the United States Department of Defense (DoD) in support of the Replicator initiative, which outlines the DOD's plan to field thousands of autonomous systems across multiple warfighting domains.

Key Points: 
  • RapidFlight is immediately capable of producing and delivering thousands of UAVs to the DoD and foreign allies.
  • Following a groundbreaking demonstration at Technology Readiness Experimentation 2023 (TREX23-2) in Camp Atterbury, Indiana, last year, RapidFlight has solidified its position as an industry leader by successfully demonstrating the company's ability to print, assemble, and fly long-range, high-payload unmanned aircraft in support of the Replicator Initiative.
  • RapidFlight's portfolio of UAS solutions, including the versatile E2 UAS , increase mission capability by three to five times when compared to the cost of existing solutions in the market.
  • RapidFlight will be providing a comprehensive view into its technology at XPONENTIAL 2024, booth 4707.

Yield10 Bioscience Reports that Proprietary Varieties of Winter Camelina Show Tolerance to Commonly Used Herbicides in First Field Tests

Retrieved on: 
Donnerstag, Februar 29, 2024
Weed control, Soil, Yield10 Bioscience, Plant, IMI, Lead, Group 2, Herbicide, USDA, Agriculture

Yield10 has previously reported herbicide tolerance in spring Camelina, where the Company has selected lead and back-up commercial-quality lines for development.

Key Points: 
  • Yield10 has previously reported herbicide tolerance in spring Camelina, where the Company has selected lead and back-up commercial-quality lines for development.
  • Preliminary interim results of these field tests indicated that Yield10’s stacked HT winter Camelina performed well on the field plots pre-treated with Group 2 herbicides.
  • The winter Camelina was planted, and the field plots were subsequently sprayed with glufosinate in accordance with the field trial design.
  • Winter Camelina engineered with glufosinate tolerance remained healthy, while field plots of Camelina without the herbicide tolerance trait did not survive the spray.

Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health

Retrieved on: 
Dienstag, März 5, 2024
Biotechnology, Pharmaceutical, AIDS, General Health, Health, Infectious Diseases, Hospitals, Clinical Trials, Bictegravir, ARV, CD4, Week, Doctor of Philosophy, Aes, Gilead Sciences, Fungal infection, Research, CROI, MDR, MD, Diarrhea, Science, Food, Female, Hook effect, ZAB, Conference, Constipation, European, Safety, Group 2, Black, Lancet, COVID-19, RNA, Public, Patient, Lenacapavir, Plasma, TAB, Observational study, HIV, Viral load

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of key data highlighting the breadth of its innovative HIV treatment research pipeline.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of key data highlighting the breadth of its innovative HIV treatment research pipeline.
  • “The latest findings across our HIV pipeline showcase the potential of multiple candidates to help transform HIV management,” said Jared Baeten, MD, PhD, Vice President, HIV Clinical Development, Gilead Sciences.
  • It is estimated that up to 10% of people with HIV take a complex treatment regimen, defined as 2 or more pills each day.
  • Results showed that all three treatment groups had robust virologic suppression at six months, with consistently low viral loads throughout the study.

Rebamipide May Combat Low-Grade Inflammation in Post-COVID-19 Syndrome Patients

Retrieved on: 
Montag, Februar 19, 2024
Group 1, Coronavirus, AAAAI, Research, SARS-CoV-2, Doctor of Philosophy, Multimedia, Inflammation, Nonsteroidal anti-inflammatory drug, Enterocyte, Asthma, ELISA, Radical, Arthralgia, Group 2, COVID-19, CRP, COVID, Patient, Journal, Rehabilitation, Plasma, Ageing, Rebamipide, American Academy, Pharmaceutical industry

MILWAUKEE, Feb. 19, 2024 /PRNewswire-PRWeb/ -- Rebamipide may be useful for rehabilitation of patients with SARS-CoV-2 post-COVID syndrome according to new research being presented at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Washington, DC, this month.

Key Points: 
  • "This study revealed higher levels of lipopolysaccharide-binding protein, and lower levels of bacterial permeability protein in patients with post COVID syndrome.
  • Rebamipide, by reducing intestinal permeability, reduces endotoxin load, lowering the level of low-grade inflammation.
  • To explore Rebamipide's usefulness for rehabilitating SARS-CoV-2 post-COVID syndrome patients, researchers examined 62 patients, aged 42-55 years with post-COVID-19 syndrome using nonsteroidal anti-inflammatory drugs for joint pain.
  • Given the effects of SARS-CoV-2 on enterocytes, the results suggest that Rebamipide may be useful for rehabilitation of patients with SARS-CoV-2 post-COVID syndrome.

Notice convening the Annual General Meeting of AB Electrolux

Retrieved on: 
Freitag, Februar 16, 2024
Transfer, Group 1, Person, International assignment, ABS, Sale, Electrolux, Annual report, ATTN:, Election, Legislation, Housing, Nomination, Annual general meeting, Committee, The Annual Report, Social Security, AMF, Companies Act, Malus, Group 2, PwC, Remuneration, LTI, Motivation, Mass meeting, Group 4, Retirement, General counsel, CO2, Employment, Auditor, Editorial, Chapter Eight, Group 5, Corporate governance, Group 3, Group 7, Swedish Bar Association, Audit committee, Investor AB, Administration, Disability, Report, Annual, STI, Management

The Board of Directors proposes that the following guidelines for remuneration shall be approved by the Annual General Meeting of the Company.

Key Points: 
  • The Board of Directors proposes that the following guidelines for remuneration shall be approved by the Annual General Meeting of the Company.
  • The principles shall be applied to employment and consultancy agreements entered into after the 2024 Annual General Meeting, and to changes made to existing agreements thereafter.
  • The proposal to the 2024 Annual General Meeting for resolution on guidelines for remuneration corresponds, in all material aspects, with the guidelines adopted by the 2020 Annual General Meeting.
  • The resolution of the Annual General Meeting to implement the Share Program 2024 according to a) above requires that more than half of the votes cast at the Annual General Meeting are in favor of the proposal.

Notice convening the Annual General Meeting of AB Electrolux

Retrieved on: 
Freitag, Februar 16, 2024
Transfer, Group 1, Person, International assignment, ABS, Sale, Electrolux, Annual report, ATTN:, Election, Legislation, Housing, Nomination, Annual general meeting, Committee, The Annual Report, Social Security, AMF, Companies Act, Malus, Group 2, PwC, Remuneration, LTI, Motivation, Mass meeting, Group 4, Retirement, General counsel, CO2, Employment, Auditor, Editorial, Chapter Eight, Group 5, Corporate governance, Group 3, Group 7, Swedish Bar Association, Audit committee, Investor AB, Administration, Disability, Report, Annual, STI, Management

The Board of Directors proposes that the following guidelines for remuneration shall be approved by the Annual General Meeting of the Company.

Key Points: 
  • The Board of Directors proposes that the following guidelines for remuneration shall be approved by the Annual General Meeting of the Company.
  • The principles shall be applied to employment and consultancy agreements entered into after the 2024 Annual General Meeting, and to changes made to existing agreements thereafter.
  • The proposal to the 2024 Annual General Meeting for resolution on guidelines for remuneration corresponds, in all material aspects, with the guidelines adopted by the 2020 Annual General Meeting.
  • The resolution of the Annual General Meeting to implement the Share Program 2024 according to a) above requires that more than half of the votes cast at the Annual General Meeting are in favor of the proposal.

FDA Approves First Medication to Treat Severe Frostbite

Retrieved on: 
Mittwoch, Februar 14, 2024
Human services, Group 1, Blood pressure, Division, Research, Aspirin, Headache, The, Frostbite, Cosmetics, Multimedia, Group 3, Flushing, Blood, Physician, FDA, Dietary supplement, Food, Dizziness, Skin, Nausea, Finger, Cardiology, Vomiting, Standard of care, Vaccine, Risk, Animal, Iloprost, Amputation, Safety, Heated tobacco product, Group 2, Nephrology, Public, Patient, Palpitations, Orthostatic hypertension, Hypotension, Priority review

SILVER SPRING, Md., Feb. 14, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Aurlumyn (iloprost) injection to treat severe frostbite in adults to reduce the risk of finger or toe amputation.

Key Points: 
  • SILVER SPRING, Md., Feb. 14, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Aurlumyn (iloprost) injection to treat severe frostbite in adults to reduce the risk of finger or toe amputation.
  • Frostbite can occur in several stages, ranging from mild frostbite that does not require medical intervention and does not cause permanent skin damage, to severe frostbite when both the skin and underlying tissue are frozen and blood flow is stopped, sometimes requiring amputation.
  • Iloprost's efficacy in treating severe frostbite was primarily established in an open-label, controlled trial that randomized 47 adults with severe frostbite, who all received aspirin by vein and standard of care, into one of three treatment groups.
  • The two other groups received other medications that are unapproved for frostbite, given with iloprost (Group 2) or without iloprost (Group 3).

Emergex Announces Authorisation from Philippines FDA to Initiate Phase I-II Clinical Trial of CoronaTcP™

Retrieved on: 
Mittwoch, Januar 3, 2024
Entrepreneurship, CD8, FDA, Group 2, Disease, Trial of the century, Vaccination, Mutation, Water, Volunteering, SARS-CoV-2, Safety, Coronavirus, Group 1, Vaccine

Emergex received authorisation from the Philippines FDA to launch a Phase I-II clinical trial of CoronaTcP, its T cell-priming immune set-point candidate against Betacoronaviruses.

Key Points: 
  • Emergex received authorisation from the Philippines FDA to launch a Phase I-II clinical trial of CoronaTcP, its T cell-priming immune set-point candidate against Betacoronaviruses.
  • Emergex is progressing trial initiation plans, with an anticipated start date in Q2 2024.
  • The naNO-COVID 2 trial (NCT05633446) is a randomized, double-blind, placebo-controlled Phase I-II trial in the Philippines, which will investigate the safety and immunogenicity of CoronaTcP.
  • Professor Thomas Rademacher, Co-Founder and Chief Executive Officer, Emergex, commented: “We thank the Philippines FDA for rapidly approving this trial after a successful Phase I clinical trial in Switzerland.